T1	Participants 61 137	patients recruited into the Carvedilol or Metoprolol European Trial (COMET).
T2	Participants 338 408	patients with heart failure and left ventricular systolic dysfunction.
T3	Participants 922 1041	Almost all patients were receiving diuretics and ACE inhibitors with few patients taking angiotensin receptor blockers.
